INT41893

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 1983
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 16
Total Number 17
Disease Relevance 8.98
Pain Relevance 1.19

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (HBS1L) translation (HBS1L) GTPase activity (HBS1L)
Anatomy Link Frequency
blood 2
liver 1
red blood cell 1
HBS1L (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 17 87.76 High High
Inflammation 6 83.96 Quite High
Versed 5 82.72 Quite High
analgesia 10 82.56 Quite High
fibrosis 4 81.28 Quite High
Opioid 5 79.68 Quite High
tolerance 15 79.24 Quite High
Analgesic 5 78.16 Quite High
Lasting pain 5 76.60 Quite High
cva 5 54.16 Quite High
Disease Link Frequency Relevance Heat
Hepatitis 150 100.00 Very High Very High Very High
Hepatitis B Virus Infection 535 99.76 Very High Very High Very High
Malaria 112 99.48 Very High Very High Very High
Stroke 5 97.80 Very High Very High Very High
Sickle Cell Anemia 210 97.46 Very High Very High Very High
Sprains And Strains 4 97.44 Very High Very High Very High
Asymptomatic Infections 17 93.44 High High
Pressure Volume 2 Under Development 45 89.00 High High
Infection 155 87.12 High High
Cirrhosis 23 83.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
By contrast, there was a significant effect of HbS (heterozygote plus homozygote) on gametocyte positivity.
Negative_regulation (effect) of HbS
1) Confidence 0.23 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2894056 Disease Relevance 0.41 Pain Relevance 0
5-Azacytidine, given to one sickle cell patient as 9 doses of 30 mg/m2 each at intervals of 8 hr, rapidly increased the number of red cells containing HbF (F cells), decreased the amount of HbS in F cells, and decreased the MCHC of F cells.
Negative_regulation (decreased) of HbS associated with sickle cell anemia
2) Confidence 0.23 Published 1983 Journal Prog. Clin. Biol. Res. Section Abstract Doc Link 6198661 Disease Relevance 0.25 Pain Relevance 0.09
The odd ratios in Hausa for the protective effect of HbS in clinical malaria versus population control (no malaria group was: OR = 3.98; P = 0.01, while the odd ratio for asymptomatic malaria versus clinical malaria was: OR = 8.18; P = < 0.0001.
Negative_regulation (effect) of HbS associated with malaria
3) Confidence 0.14 Published 2010 Journal BMC Med Genet Section Body Doc Link PMC2829010 Disease Relevance 0.63 Pain Relevance 0
Based on pathophysiology and clinical experience, the substitution of oxygen carriers and reduction of HbS below 30% to 40% is recommended [6,10].
Negative_regulation (reduction) of HbS
4) Confidence 0.04 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2838918 Disease Relevance 0.40 Pain Relevance 0.33
It is not clear whether reducing the proportion of HbS minimizes perioperative complications, or whether patients with SCD in a stable clinical condition benefit from an exchange blood transfusion in the perioperative setting.
Spec (whether) Negative_regulation (reducing) of HbS in blood associated with sickle cell anemia
5) Confidence 0.03 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2838918 Disease Relevance 0.41 Pain Relevance 0.03
The blood was replaced using red blood cell concentrate and normal saline (1:2) This partial exchange transfusion decreased the HbS fraction to 21.6%; afterwards, haemoglobin HPLC revealed that his HbA2 was 7.4% and HbF was 1.9%.
Negative_regulation (decreased) of HbS in red blood cell
6) Confidence 0.03 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2838918 Disease Relevance 0.51 Pain Relevance 0.04
In contrast, Vichinsky et al. [3] compared aggressive exchange blood transfusion (which reduced HbS to < 30%) to a conservative transfusion regime (which increased haemoglobin to 6.3 mmol/litre) and found out that the complication rate (which was about 15%) did not differ.
Negative_regulation (reduced) of HbS in blood
7) Confidence 0.03 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2838918 Disease Relevance 0.28 Pain Relevance 0.24
The degree to which HbS is reduced seems to generally correlate with reduced complication rates [9].
Negative_regulation (reduced) of HbS
8) Confidence 0.03 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2838918 Disease Relevance 0.52 Pain Relevance 0.36
After 1 year of treatment, 4 patients (23.5%; 95% CI = 9–47.7) achieved undetectable levels of serum HBV DNA, while HBsAg loss was recorded in 7 patients (41.2%; 95% CI = 21.5–64) and sustained normalized alanine aminotransferase (ALT) was reported in 13 patients (76.5%; 95% CI = 52.2–90.9).
Negative_regulation (loss) of HBsAg associated with hepatitis b virus infection
9) Confidence 0.02 Published 2005 Journal J Int AIDS Soc Section Body Doc Link PMC2740790 Disease Relevance 0.42 Pain Relevance 0
Villenueve recently reported the first case of a patient who developed sequential selection of LAM and ADV resistant strains of HBV in a liver transplantation patient. [20] The patient was a 52 year old Cambodian who was initially HBV DNA negative and HBsAg positive.
Negative_regulation (positive) of HBsAg in liver associated with hepatitis b virus infection and sprains and strains
10) Confidence 0.01 Published 2006 Journal Ann Clin Microbiol Antimicrob Section Body Doc Link PMC1459192 Disease Relevance 0.61 Pain Relevance 0
More importantly, loss of HBsAg with development of hepatitis B surface antibody (anti-HBs) was achieved in 8 of the 271 patients (3.0%) on pegylated interferon alpha-2a monotherapy, 8 of the 271 patients (3.0%) on pegylated interferon alpha-2a plus lamivudine combination therapy, and none of the 272 patients (0%) on lamivudine monotherapy (p=0.004 for both comparisons) (Lau, Piratvisuth, et al 2005).


Negative_regulation (loss) of HBsAg associated with hepatitis
11) Confidence 0.01 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 0.55 Pain Relevance 0.04
In those with detectable HBV DNA after HBeAg seroconversion, the HBV DNA will be undetectable in 60%–100% of those who lose HBsAg.
Negative_regulation (lose) of HBsAg associated with hepatitis b virus infection
12) Confidence 0.01 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 1.01 Pain Relevance 0
In Caucasians, the long-term durability of HBeAg is as high as 90% (Niederau et al 1996), while around 20%–70% of patients with loss of HBeAg and hepatitis B e antibody (anti-HBe) seroconversion will eventually lose hepatitis B surface antigen (HBsAg) (Niederau et al 1996; Lau et al 1997).
Negative_regulation (lose) of HBsAg associated with hepatitis
13) Confidence 0.01 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 1.02 Pain Relevance 0.03
Most importantly, loss of HBsAg occurred in 7 patients receiving pegylated interferon alpha-2a monotherapy (5 Asians and 2 Caucasians) and in 5 patients receiving combination pegylated interferon alpha-2a plus lamivudine therapy (4 Asians and 1 Caucasian).
Negative_regulation (loss) of HBsAg
14) Confidence 0.01 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426802 Disease Relevance 0.26 Pain Relevance 0
The efficacy of hepatitis B therapies are therefore measured by such surrogate endpoints as HBV DNA suppression, normalization of biochemical markers (alanine aminotransferase [ALT], aspartate aminotransferase [AST]), loss of hepatitis B e antigen (HBeAg) and seroconversion to hepatitis B e antibody (anti-HBe), and loss of hepatitis B surface antigen (HBsAg).
Negative_regulation (loss) of HBsAg associated with hepatitis b virus infection and hepatitis
15) Confidence 0.01 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.95 Pain Relevance 0.04
Secondary outcomes were histologic response, change in HBV DNA levels, HBeAg loss, HBsAg loss, HBeAg seroconversion, HBsAg seroconversion, and normalization of ALT.
Negative_regulation (loss) of HBsAg associated with hepatitis b virus infection
16) Confidence 0.01 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.55 Pain Relevance 0
HBsAg loss and HBsAg seroconversion were low with both treatments, as they have been with other nucleoside analogues.
Negative_regulation (loss) of HBsAg
17) Confidence 0.01 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2762437 Disease Relevance 0.19 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox